StockData
Vaccinex, Inc. logo

Vaccinex, Inc. (VCNX) stock

VCNXOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2024, quarter ended Dec 31, 2024Last filing: 10-K on Apr 15, 2025
$1.00−0.01 (-0.99%)

Close on Oct 19, 2026Market cap $3.22MP/E –Yield –

Vaccinex free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Vaccinex's free cash flow for the twelve months ending Dec 31, 2024 was -$16.21M. For fiscal 2024 it was -$16.21M. The highest annual figure on record is -$16.21M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$16.21M–
FY2023Dec 31, 2023-$21.45M–
FY2022Dec 31, 2022-$19.17M–
FY2021Dec 31, 2021-$25.33M–
FY2020Dec 31, 2020-$28.94M–
FY2019Dec 31, 2019-$30.79M–
FY2018Dec 31, 2018-$25.51M–
FY2017Dec 31, 2017-$21.46M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024-$3.93M–
Q3 FY2024Sep 30, 2024-$3.22M–
Q2 FY2024Jun 30, 2024-$4.43M–
Q1 FY2024Mar 31, 2024-$4.63M–
Q4 FY2023Dec 31, 2023-$7.74M–
Q3 FY2023Sep 30, 2023-$3.11M–
Q2 FY2023Jun 30, 2023-$5.51M–
Q1 FY2023Mar 31, 2023-$5.09M–
Q4 FY2022Dec 31, 2022-$4.60M–
Q3 FY2022Sep 30, 2022-$4.20M–
Q4 FY2021Dec 31, 2021-$5.14M–
Q3 FY2021Sep 30, 2021-$6.07M–
Q4 FY2020Dec 31, 2020-$6.38M–
Q3 FY2020Sep 30, 2020-$9.34M–
Q2 FY2020Jun 30, 2020-$5.45M–
Q1 FY2020Mar 31, 2020-$7.76M–
Q4 FY2019Dec 31, 2019-$5.80M–
Q3 FY2019Sep 30, 2019-$10.50M–
Q4 FY2018Dec 31, 2018-$7.73M–
Q3 FY2018Sep 30, 2018-$7.23M–
Q2 FY2018Jun 30, 2018-$5.35M–
Q1 FY2018Mar 31, 2018-$5.21M–
Q4 FY2017Dec 31, 2017-$6.25M–
Q3 FY2017Sep 30, 2017-$4.74M–

More Vaccinex figures

See a number that looks wrong?